Home » Newsletters » BioWorld Science

BioWorld Science

June 23, 2006

View Archived Issues

Tanabe Seiyaku presents clinical highlights of past year

Nilotinib highlights from ASCO 2006

Recent data from lapatinib clinical trials presented

MBP-8298 delays multiple sclerosis progression in HLA class II subgroup

Analysis correlates efaproxiral concentrations with clinical benefit

Takara Bio to jointly develop AIDS gene therapy with China institute

Pivotal study of rhThrombin completes enrollment

IMPACT studies of OvaRex complete enrollment

Trials further reveal indiplon efficacy and safety in patients with insomnia

Effects of CX-717 on EEG spectra assessed after sleep deprivation

Novel histamine H1 agonist as a clinical candidate for sleep maintenance insomnia

VEC-162: rapidly shifts circadian phases to improve sleep properties

Roche and Evotec partner in CNS drug discovery and development

T-5224 enters phase I in Japan for rheumatoid arthritis

rEV-131 studied in new trial for inflammation following cataract surgery

SkyePharma reviews pipeline development

Schering AG acquires Celera Genomics' cathepsin S inhibitor program

Lundbeck to advance Lu-AA21004 for depression

CTCE-0214 to be studied for repopulating blood stem cell

Athenagen to begin phase I/II study of wound healing agent ATG-002

AEterna Zentaris to advance cetrorelix into phase III for BPH

NDA submission for Cyanokit for cyanide poisoning

Orphan drug designation for MORAb-003 in ovarian cancer

EMEA recommends orphan drug designation for GV-1001 in pancreatic cancer

European approval of Acomplia

Arginase: a novel target for diabetes

Inhibition of hepatic micro RNA regulates lipid metabolism in vivo

Novel treatment options for metabolic disorders described in recent patents

Novel agents for cardiovascular disorders disclosed

Recent patents describe therapeutic agents for respiratory disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...